Kim Henriksen's Biography

Kim Henriksen, Head, Nordic Bioscience A/S

Kim Henriksen, M.Sc., PhD has during the last ten years focused his research on drug discovery and development of novel biomarkers within the fields of Alzheimer’s disease, osteoporosis and diabetes.
The biochemical marker work has been focused on investigating and validating novel blood-based biomarkers for Alzheimer’s disease, with emphasis on the application of post-translational modifications (protein fingerprints), such as enzymatic cleavage sites, oxidations, phosphorylations, citrullinations and glycations, in relation to how these are altered in tissues undergoing pathological remodeling. This has led to the identification of an enzyme generated fragment of the neuronal protein Tau, which when measured in blood, from Alzheimer’s disease patients, correlates with cognitive function. A series of additional Tau fragments are now undergoing clinical validation tests. He is a member of the Blood Based Biomarkers Interest Group (BBBIG), an international working group of academia and industry experts in the field, and was the lead writer on the white paper for this group entitled: The future of blood-based biomarkers for Alzheimer’s disease, which has now been accepted for publication by Alzheimer’s & Dementia.
The pharmacological work has resulted in the development of a large pharmacological program for the identification of inhibitors of the chloride channel ClC-7 to be used for treatment of osteoporosis. In addition, he is an integral part of a pharmacological program focused on the development of a dual acting calcitonin and amylin receptor agonist as a treatment for type 2 diabetes. The efforts have resulted in more than 100 publications in peer-reviewed journals during the last 10 years, with an H-index of 24.